Core technology

       The DEAD/H box protein family is the largest RNA helicase protein family which can be found in all eukaryotic cells, most eukaryotic bacteria, and archaea. As early as 1988, scientists discovered that multiple proteins in the genome have some conserved sequences similar to eIF4A through sequence alignment. Later, it was determined that they mainly contain nine conserved motifs, one of which is the Asp Glu Ala Asp/His (DEAD/H) sequence. The human genome contains 37 DEAD box family members and 16 DEAH box family members. DEAD/H box proteins have the function of unwinding RNA, utilizing the hydrolysis of ATP/NTP to alter the conformation of RNA protein complexes, thereby participating in a series of RNA metabolic activities from transcription to degradation. Their function is not limited to modifying RNA molecules. Multiple studies have shown that some DEAD/H box proteins such as DHX9, DDX59, and DDX5 are also involved in DNA metabolism.

RNA helicases play an important role in the gene expression of eukaryotes, and their functions involve embryonic development, cell proliferation, hematopoiesis, metabolism, cancer, immune regulation, inflammatory response, and autoimmune diseases. Their dysregulation is correlated to various human diseases, such as cancer and viral infections. Some DEAD/H box proteins are considered as therapeutic targets for diseases, such as inhibitors of eIF4A and DDX3X, which are currently being developed as novel targeted drugs for the treatment of human cancer.

Given the close correlation between RNA helicase and human diseases,   inhibitors of some helicases have been successfully developed and currently there are several clinical trials onoing for cancer treatment and antiviral drug applications.

KeYe Life has established the screening system for the activity of various human RNA helicase proteins, committed to developing multiple original RNA helicase small molecule inhibitors for drug development. Based on over a decade of basic research, KeYe Life has developed a unique target for specific RNA helicases as cancer treatments. And we have developed small molecule inhibitors targeting RNA helicase to treat various tumors. After more than a decade of professional research, we have achieved significant results in cell and animal experiments, and are internationally leading and original, classified as Class 1.1 original new drugs.